Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02158039 · ClinicalTrials.gov registry record · Phase 1
Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02158039: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02158039 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02158039, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Cystic tumors of the pancreas are fluid-filled growths. They are often treated by surgical removal. A safe and effective non-surgical treatment is desirable. Ethanol (alcohol) injection may treat cysts by killing the lining cells of the cyst, and is an accepted treatment for cysts of other organs. In this study, participants with pancreatic cysts underwent endoscopic ultrasound (EUS) guided ethanol injection of pancreatic cysts. This was a pilot study to assess safety and efficacy. The hypotheses of this study were 1) complications of EUS guided ethanol injection requiring hospitalization will occur in \<10% of subjects, and 2) EUS guided ethanol injection, with retreatment as necessary, will ablate at least 50% of pancreatic cysts.
Interventions
- DRUG Lidocaine
- DRUG Ethanol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2004-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02158039
The ClinicalTrials.gov registry entry for NCT02158039 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lidocaine is the first listed.
NCT02158039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02158039 about?
NCT02158039 is a clinical study titled "Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms". Cystic tumors of the pancreas are fluid-filled growths. They are often treated by surgical removal. A safe and effective non-surgical treatment is desirable. Ethanol (alcohol) injection may treat cysts by killing the lining cells of the cyst, and is an accepted treatment for cysts of other organs. I...
What is the current status of trial NCT02158039?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2004-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02158039?
The interventions under investigation include: Lidocaine (DRUG), Ethanol (DRUG).
Who is sponsoring clinical trial NCT02158039?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.